Fully Human Phage Library We have obtained several monoclonal antibodies and bi-specific antibodies rapidly screened from our phage library, these antibodies are entering or have been in clinical studies.
Mouse Hybridoma Antibody Humanization For complicate targets such as GPCR family proteins and targets requiring special antibody functions, mouse hybridoma technology is used to ensure the diversity of candidates, and the final candidates are obtained through humanization technology.
Single Domain Antibody It is suitable for screening more stable and high-yield single domain antibodies， which are smaller, more stable than conventional antibodies, and can recognize novel epitopes. Moreover, it has better penetration and accessibility to tumor tissues and microenvironment.
CD3 Engager Our CD3 Engaging antibody platform (Leadsbody®) has a variety of designs for different targets, including binding to TAA with varying expression levels, CD3 affinity fine-tuning and tumor conditional activation, different valency and spatial structure, to achieve balance between efficacy and safety. A couple of CD3 engaging antibodies for the treatment of solid and liquid tumors have entered preclinical development stage with strong anti-tumor efficacy and good safety profile, and currently are being investigated in clinical studies.
Bifunctional Fusion Protein/Bispecific Antibody (Y-Abs®, L-mabs®, comL-Abs®) The bifunctional fusion protein and bispecific antibody consist of monoclonal antibodies or fusion proteins targeting various targets, to achieve bifunctional effects or reduce the side effects through improved tumor targeting. Based on antibody engineering technology, we have currently established unique MabFusion platform, common light chain bispecific antibody platform (comL-Abs®), etc., which can be used for the development of various symmetric or asymmetric bifunctional fusion proteins/bispecific antibodies.
4-1BB Engager Our 4-1BB engager platform is developed by utilizing antibody engineering technology to balance the affinity between TAA and 4-1BB, crosslinking and activating the 4-1BB receptor through binding to TAA targets, thereby maximizing the function of targeting 4-1BB. In vivo studies have demonstrated that it promotes the activation and proliferation of effector T cells, improves tumor infiltration, inhibits Treg cells by boosting immune system in TME while avoiding the risk of toxicities associated with CRS. LBL-024 was designed based on the 4-1BB engager platform and is shown its great tolerability and efficacy in clinical studies.